OPTN: OptiNose, Inc. - Summary | Jitta

OptiNose, Inc.

NASDAQ:OPTN

Notice
Stock data is unavailable or the company’s delisted.
Price
$9.60
Loss Chance
51.0%
3.77JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (70)
Recent Business Performance (53)
Financial Strength (28)
Return to Shareholders (13)
Competitive Advantage (54)
Jitta Signs
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2024
Recent Business PerformanceEarning decline 23.95% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
3.77
100.00%
2.22
281.50%
2.22
281.50%
COMPANY DESCRIPTION
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.